Biologicals in asthma

Evaluation of Omalizumab and Mepolizumab Treatment Efficacy in Severe Asthmatics Associated with NSAID-Exacerbated Airway Disease (N-ERD)

Predicting factors for response to mepolizumab after 3 years of follow up in patients with severe eosinophilic asthma